{"filing":{"accession_number":"0001829126-26-007585","cik":"0001979414","ticker":"NTHI","company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","form":"8-K","filing_date":"2026-07-15","report_date":null,"primary_document":"neonctechnologies_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1979414/000182912626007585/neonctechnologies_8k.htm"},"events":[{"id":18055,"run_id":16208,"accession_number":"0001829126-26-007585","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"NeOnc disclosed receipt of written FDA feedback on the chemistry, manufacturing and controls (CMC) development program for its lead drug candidate NEO212, including specific guidance on formulation, bioavailability studies, and manufacturing requirements. This is a material regulatory milestone for a clinical-stage biotech company that clarifies the path forward for late-stage development of a key asset, though it is not a formal approval or agreement on trial design. The disclosure is operational in nature—relating to drug development strategy and regulatory guidance—rather than financial, governance, or legal.","company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","filing_date":"2026-07-15","form":"8-K","submitted_at":null,"items":[{"id":16756,"accession_number":"0001829126-26-007585","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"NeOnc disclosed receipt of written FDA feedback on the chemistry, manufacturing and controls (CMC) development program for its lead drug candidate NEO212, including specific guidance on formulation, bioavailability studies, and manufacturing requirements. This is a material regulatory milestone for a clinical-stage biotech company that clarifies the path forward for late-stage development of a key asset, though it is not a formal approval or agreement on trial design. The disclosure is operational in nature—relating to drug development strategy and regulatory guidance—rather than financial, governance, or legal.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T13:16:42.590430+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16756,"accession_number":"0001829126-26-007585","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"NeOnc disclosed receipt of written FDA feedback on the chemistry, manufacturing and controls (CMC) development program for its lead drug candidate NEO212, including specific guidance on formulation, bioavailability studies, and manufacturing requirements. This is a material regulatory milestone for a clinical-stage biotech company that clarifies the path forward for late-stage development of a key asset, though it is not a formal approval or agreement on trial design. The disclosure is operational in nature—relating to drug development strategy and regulatory guidance—rather than financial, governance, or legal.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T13:16:42.590430+00:00","company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","filing_date":"2026-07-15"}]}